ERYTECH PHARMA (ERYP.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ERYP - FR0011471135 - Common Stock
0.801 EUR
+0 (+0.25%)
We assign a fundamental rating of 2 out of 10 to ERYP. ERYP was compared to 86 industry peers in the Biotechnology industry. ERYP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ERYP is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year ERYP has reported negative net income.
- In the past year ERYP has reported a negative cash flow from operations.
1.2 Ratios
- The profitability ratios for ERYP are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for ERYP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ERYP does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, ERYP has about the same amount of shares outstanding.
- The debt/assets ratio for ERYP has been reduced compared to a year ago.
2.2 Solvency
- ERYP has an Altman-Z score of -2.53. This is a bad value and indicates that ERYP is not financially healthy and even has some risk of bankruptcy.
- ERYP has a Altman-Z score (-2.53) which is in line with its industry peers.
- ERYP has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
- ERYP has a Debt to Equity ratio (0.44) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.53 |
ROIC/WACCN/A
WACC5.06%
2.3 Liquidity
- ERYP has a Current Ratio of 3.65. This indicates that ERYP is financially healthy and has no problem in meeting its short term obligations.
- With a decent Current ratio value of 3.65, ERYP is doing good in the industry, outperforming 72.84% of the companies in the same industry.
- A Quick Ratio of 3.65 indicates that ERYP has no problem at all paying its short term obligations.
- ERYP's Quick ratio of 3.65 is fine compared to the rest of the industry. ERYP outperforms 75.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.65 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
- ERYP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.68%, which is quite impressive.
- Looking at the last year, ERYP shows a very strong growth in Revenue. The Revenue has grown by 59.04%.
- ERYP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.60% yearly.
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.44%
Revenue 1Y (TTM)59.04%
Revenue growth 3Y7.96%
Revenue growth 5Y14.6%
Sales Q2Q%198.12%
3.2 Future
- ERYP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.28% yearly.
- The Revenue is expected to decrease by -44.77% on average over the next years. This is quite bad
EPS Next Y22.35%
EPS Next 2Y26.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.44%
Revenue Next 2Y16.85%
Revenue Next 3Y-56.11%
Revenue Next 5Y-44.77%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ERYP. In the last year negative earnings were reported.
- Also next year ERYP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as ERYP's earnings are expected to grow with 26.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.28%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for ERYP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ERYTECH PHARMA / ERYP.PA FAQ
What is the ChartMill fundamental rating of ERYTECH PHARMA (ERYP.PA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to ERYP.PA.
What is the valuation status for ERYP stock?
ChartMill assigns a valuation rating of 2 / 10 to ERYTECH PHARMA (ERYP.PA). This can be considered as Overvalued.
Can you provide the profitability details for ERYTECH PHARMA?
ERYTECH PHARMA (ERYP.PA) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for ERYP stock?
The Earnings per Share (EPS) of ERYTECH PHARMA (ERYP.PA) is expected to grow by 22.35% in the next year.